BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
2/5/2024 12:08:48 PM | Browse: 213 | Download: 717
 |
Received |
|
2023-10-06 10:28 |
|
Peer-Review Started |
|
2023-10-06 10:31 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2023-11-12 04:40 |
|
Revised |
|
2023-11-26 17:50 |
|
Second Decision |
|
2023-12-29 02:43 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2023-12-29 05:41 |
|
Articles in Press |
|
2023-12-29 05:41 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2024-01-02 20:34 |
|
Typeset the Manuscript |
|
2024-01-29 12:09 |
|
Publish the Manuscript Online |
|
2024-02-05 12:08 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Clinical Trials Study |
| Article Title |
Optimized sequential therapy vs 10 and 14-d concomitant therapy for eradicating Helicobacter pylori: A randomized clinical trial
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Hassan Seddik, Jihane Benass, Sanaa Berrag, Asmae Sair, Reda Berraida and Hanae Boutallaka |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Jihane Benass, MD, N/A, N/A, Department of Gastroenterology II, Mohammed V Military Teaching Hospital of Rabat, Avenue des Forces Armées Royales, Rabat 10100, Morocco. jihane.benass@gmail.com |
| Key Words |
Helicobacter pylori; Quadruple therapy; Sequential; Proton-pump inhibitor; Optimization |
| Core Tip |
Helicobacter pylori infection remains currently a common infection worldwide. The decline in the efficacy of traditional triple therapies has generated since 2010 new combinations of antibiotics. The last guidelines of Maastricht VI recommend bismuth quadruple therapies or concomitant quadruple therapies to reach an eradication rate of at least 90%. These values remain higher than those obtained with standard sequential therapy, but are associated to a higher cost and to more adverse effects (AEs). The results of the present study showed that optimizing the sequential therapy by using second-generation proton-pump inhibitors improved the eradication rate and reduced the AEs incidence. This combination can thus be suggested for use in clinical practice. |
| Publish Date |
2024-02-05 12:08 |
| Citation |
Seddik H, Benass J, Berrag S, Sair A, Berraida R, Boutallaka H. Optimized sequential therapy vs 10 and 14-d concomitant therapy for eradicating Helicobacter pylori: A randomized clinical trial. World J Gastroenterol 2024; 30(6): 556-564 |
| URL |
https://www.wjgnet.com/1007-9327/full/v30/i6/556.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v30.i6.556 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
